Valuation: Algorae Pharmaceuticals Limited

Market Cap 18.25M 13.01M 11.27M 10.66M 9.65M 18.11M 1.25B 127M 48.94M 633M 48.88M 47.8M 2.02B P/E 2025
-10x
P/E 2026 -6.55x
Enterprise Value 14.31M 10.21M 8.84M 8.36M 7.57M 14.2M 979M 99.76M 38.38M 496M 38.34M 37.49M 1.58B EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
66.95%
Yield 2025 *
-
Yield 2026 -
1 day-10.00%
1 week-18.18%
Current month-10.00%
1 month-18.18%
3 months-18.18%
6 months-40.00%
Current year-35.71%
1 week 0.01
Extreme 0.009
0.01
1 month 0.01
Extreme 0.009
0.01
Current year 0.01
Extreme 0.009
0.02
1 year 0.01
Extreme 0.007
0.02
3 years 0
Extreme 0.005
0.02
5 years 0
Extreme 0.003999
0.02
10 years 0
Extreme 0.003999
0.28
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2023-06-18
Corporate Secretary - 2026-06-30
Corporate Secretary - 2026-06-30
Director TitleAgeSince
Chairman 52 2023-01-04
Director/Board Member - 2026-03-09
Director/Board Member 52 2026-07-13
Change 5-day change 1-year change 3-year change Capi.($)
-10.00%-18.18%+28.57%-33.33% 14.47M
-1.38%+0.20%+46.42%+96.33% 70.24B
-1.04%-0.81%+34.61%+75.16% 62.63B
-4.29%-3.98%-16.22%+350.66% 27.36B
+1.79%+2.68%+29.39%+15.02% 25.71B
-2.20%-2.00%-1.22%-14.48% 24.83B
+1.61%-0.69%+20.85%-19.42% 19.52B
+1.26%-14.23%+170.04%+298.75% 15.51B
-5.54%+0.69%-8.13%+830.48% 14.69B
-1.08%-4.66%-10.25%+452.53% 14.66B
Average -2.05%-2.88%+29.41%+205.17% 27.52B
Weighted average by Cap. -1.19%-1.32%+30.83%+160.58%

Financials

2025 2026
Net sales - -
Net income -803K -573K -496K -469K -425K -797K -54.93M -5.6M -2.15M -27.85M -2.15M -2.1M -88.83M -2.71M -1.93M -1.67M -1.58M -1.43M -2.69M -185M -18.9M -7.27M -94.03M -7.26M -7.1M -300M
Net Debt -2.32M -1.65M -1.43M -1.35M -1.23M -2.3M -159M -16.17M -6.22M -80.45M -6.21M -6.08M -257M -3.94M -2.81M -2.43M -2.3M -2.08M -3.91M -269M -27.45M -10.56M -137M -10.55M -10.31M -436M
Logo Algorae Pharmaceuticals Limited
Algorae Pharmaceuticals Limited is an Australia-based artificial-intelligence (AI) enabled pharmaceutical development company. The Company’s proprietary AI platform, Algorae Operating System (AlgoraeOS), is an AI platform that leverages extensive medical and scientific databases from various disciplines within an advanced system at the intersection of AI and pharmaceutical research. Its other drug candidates include AI-116, AI-168, NTCELL. AI-116 is a combination drug candidate made up of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. It is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease. AI-168 is a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient, which is conceptualized to be a potential treatment for cardiovascular disease, including hypertension. NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells.
Employees
48
Date Price Change Volume
26-09-15 A$0.009000 -10.00% 1,447,580
26-09-11 A$0.0100 +11.11% 23,201
26-09-10 A$0.009000 -10.00% 50,214
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!